Epilepsy and seizure disorders
Sk Life Science Inc. focuses on clinical research in epilepsy, with particular attention to primary generalized tonic-clonic seizures, partial-onset seizures, and partial-onset (focal) seizures.
- Primary generalized tonic-clonic seizures
- Partial-onset seizures
- Partial-onset (focal) seizures
The sponsor’s research activity includes both adult and pediatric populations, reflecting a therapeutic interest in seizure control across a broad age range.
Lennox-Gastaut syndrome
The company also supports studies in Lennox-Gastaut syndrome, a severe developmental and epileptic encephalopathy associated with multiple seizure types, including drop seizures.
- Lennox-Gastaut syndrome
- Drop seizures
- Tonic, atonic, and tonic-clonic seizures
This area highlights interest in difficult-to-control seizure syndromes affecting both pediatric and adult patients.
Cenobamate development in seizure management
Sk Life Science Inc. is actively involved in clinical programs centered on cenobamate for seizure disorders, with research spanning adjunctive therapy and evaluation of treatment effects in generalized and focal epilepsies.
- Cenobamate
- Adjunctive treatment
- Safety and tolerability
Its clinical portfolio includes work in both adult and pediatric epilepsy populations.
Pediatric neurology
A notable part of the sponsor’s research landscape is the study of seizure disorders in children and adolescents, including evaluation of pharmacokinetics and treatment response in younger patients.
- Pediatric subjects
- Pharmacokinetics
- Seizure disorders in children
This emphasis supports therapeutic development for age-specific epilepsy care.
